We developed this novel research tool using a gain-of-function strategy to overexpress a molecule previously shown to be necessary and sufficient to induce muscle atrophy and a sarcopenia phenotype in mice: Atrogin-1 (Atro1) [17–19]. Here, FBXO32 is linked to sarcopenia.